Why Are Biophytis Shares Skyrocketing Today?

Biophytis SA BPTS shares are surging in premarket after the company concluded a master agreement to produce the active compound in Sarconeos (BIO101) with SEQENS.

Sarconeos (BIO101) is Biophytis' main drug candidate developed for three indications: severe forms of Covid-19, sarcopenia, and Duchenne muscular dystrophy.

SEQENS will produce the active ingredient in Sarconeos (BIO101) in France at its Villeneuve La Garenne plant. The site was modernized and expanded in 2020 with the opening of a unit to produce high-potential active pharmaceutical ingredients (APIs). 

Stanislas Veillet, Chairman and CEO of Biophytis, commented: "This partnership is an important step for Biophytis, as it enables us to secure the production of the active ingredient in our main drug candidate."

Recently, Biophytis filed for approval with the FDA to launch its SARA-31 program in the U.S., the first-ever Phase 3 study in sarcopenia.

Price Action: BPTS shares are up 45.70% at $3.22 during the premarket session on the last check Tuesday.